Related Experiment Videos
High-dose corticosteroid therapy in human septic shock: has the jury reached a correct verdict?
1Department of Infectious Diseases, University Hospital, Uppsala, Sweden.
Insights
High-dose corticosteroids (HDC) in septic shock treatment remain controversial. While past trials showed no benefit, recent data suggest a single early HDC dose may improve mortality in gram-negative septic shock.
Area of Science:
- Critical care medicine
- Pharmacology
- Infectious diseases
Background:
- High-dose corticosteroids (HDC) use in septic shock has a controversial history.
- Previous studies faced methodological criticisms, leading to recommendations against HDC.
Purpose of the Study:
- To critically compare four key 1980s trials on HDC in septic shock.
- To evaluate the aims, design, results, and conclusions of these pivotal studies.
Main Methods:
- Comparative analysis of four specific clinical trials from the 1980s.
- Discussion on the methodological validity and data interpretation of the included studies.
Main Results:
- No unequivocal evidence supports HDC benefits in septic shock across all studies.
- Significant challenges exist in conducting reliable clinical trials for septic shock patients.
Conclusions:
- Existing evidence does not definitively prove HDC efficacy in septic shock.
- Accumulated data suggest a potential mortality benefit from a single early HDC dose in gram-negative septic shock.
Abstract:
Many studies have been published concerning high-dose corticosteroids (HDC) in septic shock. Most of them have been criticized for not adhering to methodologic standards. Four studies were published during the 1980s taking into consideration the criticism of previous trials. The general conclusion following these trials was the HDC should not be used in the treatment of septic shock. The aim of this review is to compare these trials as regards their aims, study design, results, and conclusions. The validity of the data presented is discussed. It is concluded that there is no unequivocal evidence that HDC is beneficial in septic shock, but it must be realized that there are tremendous difficulties in obtaining the true state of affairs in clinical trials regarding patients in septic shock. Accumulated data indicate that HDC, given as one single dose during the initial hours of gram-negative septic shock, more likely than not has a beneficial effect on mortality.